RH Q3 2025 Earnings Recap

RYTM Q3 2025 November 6, 2025

Rhythm Pharmaceuticals reported strong Q3 2025 performance, highlighted by significant growth in IMCIVREE revenue and strategic advancements in their product pipeline, positioning the company for upcoming launches.

Earnings Per Share Miss

$-0.82 vs $-0.72 est.

-13.9% surprise

Revenue Miss

51298000 vs 55976220 est.

-8.4% surprise

Market Reaction

1-Day -0.99%

5-Day +0.39%

30-Day +5.6%

Key Takeaways

IMCIVREE sales reached $51.3 million, marking a 10% increase in reimbursed therapy patients.
Successful completion of a $189 million equity offering in July to strengthen the balance sheet ahead of key regulatory developments.
Regulatory filings for hypothalamic obesity (HO) accepted by both the FDA and EMEA, with a PDUFA date set for December 20, 2025.
Upcoming preliminary results from the Phase II trial in Prader-Willi syndrome expected by year-end, aimed at demonstrating efficacy in BMI reduction.
Expansion of the commercial team in preparation for the HO launch, targeting an estimated 10,000 patients in the U.S. market.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit RYTM on AllInvestView.